Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 12-Month Low – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) hit a new 52-week low during trading on Wednesday . The stock traded as low as $18.00 and last traded at $18.05, with a volume of 6643 shares traded. The stock had previously closed at $18.29.

Wall Street Analysts Forecast Growth

DNTH has been the subject of several research analyst reports. Guggenheim reaffirmed a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Wedbush reaffirmed an “outperform” rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. TD Cowen began coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating for the company. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $54.33.

Dianthus Therapeutics Trading Up 8.8 %

The company has a market cap of $638.32 million, a P/E ratio of -7.95 and a beta of 1.82. The stock’s 50 day moving average is $21.91 and its 200-day moving average is $24.34.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.40 million. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Large investors have recently added to or reduced their stakes in the stock. MetLife Investment Management LLC lifted its stake in shares of Dianthus Therapeutics by 3.1% in the 4th quarter. MetLife Investment Management LLC now owns 14,372 shares of the company’s stock worth $313,000 after purchasing an additional 433 shares during the period. Invesco Ltd. grew its position in shares of Dianthus Therapeutics by 7.4% during the 4th quarter. Invesco Ltd. now owns 11,521 shares of the company’s stock valued at $251,000 after acquiring an additional 790 shares during the period. SG Americas Securities LLC increased its stake in shares of Dianthus Therapeutics by 9.2% in the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock worth $210,000 after purchasing an additional 814 shares in the last quarter. Barclays PLC raised its holdings in Dianthus Therapeutics by 2.6% in the 4th quarter. Barclays PLC now owns 42,766 shares of the company’s stock worth $933,000 after purchasing an additional 1,082 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Dianthus Therapeutics by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company’s stock valued at $3,641,000 after purchasing an additional 1,092 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.